Clinical trials: COVID-19; Immunity
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2
EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all…
- Trial name
- NCT05059106
- Testing
- Half dose of ChAdOx1 nCoV-19 (AZD1222), Standard dose of ChAdOx1 nCoV-19 (AZD1222)
- Where
- Brazil
- Volunteers
- 29,637 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Vaccination
Platelet and Immune Response in Covid-19 Vaccine
COVID-19 mRNA vaccines, administered with a two-dose regimen, have been shown to provide protection against Covid-19. However, the thromboinflammatory response toward these vaccines has never been explored as they exploit a…
- Trial name
- Vax-SPEED-IT (NCT05171959)
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
SARS-CoV-2 Infection
COVID-19 VACCINE SAFETY AND EFFECTIVENESS
A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an…
- Trial name
- NCT05133609
- Testing
- ChAdOx1 nCoV-19 vaccine (AZD1222)
- Where
- Brazil
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.
- Trial name
- RePAiR (NCT04495764)
- Where
- 12 sites in United States
- Volunteers
- 2,315 people
- Sponsor
- Davita Clinical Research
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Covid19
Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or…
- Trial name
- COVID19vac-1 (NCT04706390)
- Testing
- covid-19 vaccine
- Where
- Norway
- Volunteers
- 2,500 people
- Sponsor
- University of Bergen
Influenza, COVID-19
Respiratory Virus Sampling and Repository
Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections.
- Trial name
- NCT05266222
- Where
- 2 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Community-based Sero-epidemiological Study of COVID-19
Using detailed serial cross-sectional estimates of the age-specific distribution of SARS-CoV-2 Omicron variant-specific antibody positivity levels, the investigators derived age-specific infection attack rates and age-specific…
- Trial name
- NCT05599555
- Testing
- mRNA BNT162b2 vaccine, CoronaVac vaccine
- Where
- Hong Kong
- Volunteers
- 9,600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
SARS-CoV-2 Acute Respiratory Disease
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021.
- Trial name
- COVCAL (NCT05135585)
- Testing
- Blood sample collection, Questionnaires
- Where
- 3 sites in New Caledonia
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Coronavirus 2019, Healthcare Workers
Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic.
- Conditions
- Coronavirus 2019, Healthcare Workers, Vaccine
- Trial name
- NCT04843917
- Testing
- Immunoglobulin G detection
- Where
- Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Healthy Volunteers
Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers
Background: In early 2020, many people thought Cambodia would have a serious COVID-19 outbreak due to the high number of Chinese travelers going to Cambodia.
- Trial name
- NCT04594395
- Where
- 2 sites in Cambodia
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
COVID-19, SARS-CoV2
Host Response Mediators in Coronavirus (COVID-19) Infection
The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality.
- Trial name
- ARBS CORONA I (NCT04510623)
- Testing
- ARBs and/or ACE inhibitors, Usual Care
- Where
- 15 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University of British Columbia
COVID-19 (Coronavirus Disease 2019)
Understanding COVID-19 Vaccine Immunity in Tissue and Blood
The purpose of this study is to understand the effects of COVID-19 vaccines on the immune system and how the COVID-19 vaccines provide protection and induce long term memory.
- Trial name
- NCT05682625
- Testing
- No intervention
- Where
- United States
- Sponsor
- Stanford University
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris